Hey R, good to hear from you! The problem on buying at the bottom is no one sounds a bell to let you know when it is ok to start buying. Usually the best buying opp is when things look the worst. You know, its darkest before dawn. Regarding Burill, I think what he said is mostly BS. For example
<<System Biology is the next revolution.>> Oh I see genomics, proteomics are all dead. I think they are still at the early stages
<<Value is moving from Rx (Drugs) to DX (Diagnostics) due to genomics. As you more personalize and customize drug usage, the diagnostics become more important and the drugs usage more targeted, and thus sales of each drug smaller.>>
Sorry Steve, there still is nothing like an approved patented drug for an unmet medical need. I am not saying DX wont be important but the biggest pops will be from developing drugs.
<<Biotech as an industry is near its bottom, shares are trading near their cash per share value when looked at as an industry. Much of the $40B raised in the last 2 years is still in the bank.>>
I am not smart enough to know when the bottom is. If what he means is that there are great risk rewards out there I agree.
<<Cap markets volatility will continue>>
How insightful
<<Big Bio's will continue to acquire small ones (we don't have bankruptcy, but eat our own dead).>>
assuming they have money.
<<Biotechs are THE source of innovation for the big pharmas.>>
This has been true for a while. Lets not forget the impact the academic word has and continues to make.
<<System Biology is the driving change>>
yes, and. How does that translate into opportunity
<<Increases in diagnostics to direct the therapeutic product usage.>>
Makes me feel better about my AFFX which is getting CRUSHED
<<Agbio/Nutraceuticals/BioMaterials are all emerging>>
Did he really say Agbio. I guess he is not part of the natural food mafia
<<Challenges: genethics, cloning, gene therapy, Genetically Modified Organisms (GMO's), Stem Cells>>
Is this insightful
I had enough and I am in a bad mood.
sorry
V1 |
